ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2016

Abstract Number: 2445

Dermatomyositis and Pregnancy: Assessment of Disease Activity and Pregnancy Outcomes Complicated By Maternal Dermatomyositis

Gopika Miller1, Elizabeth Moore2, Antonia Valenzuela3, Lorinda Chung4 and Victoria P. Werth5, 1Medicine, Harbor UCLA Medical Center, Torrance, CA, 2Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, 3Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 4Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 5Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: Dermatomyositis and pregnancy

Session Information

Date: Tuesday, November 15, 2016

Title: Reproductive Issues in Rheumatic Disorders - Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The effect of pregnancy on Dermatomyositis (DM) disease activity and on maternal and fetal outcomes in patients with DM is unclear. Study objective is to evaluate disease activity and pregnancy outcomes complicated by maternal dermatomyositis.

Methods: A total of 10 patients with 21 pregnancies from a cohort of 438 DM patients of child-bearing potential, diagnosed between 2006 and 2015 from two centers, were eligible for interview with a specific questionnaire regarding pregnancy and fetal outcomes.

Results: Weakness, rash and arthritis were the most common clinical symptoms that improved during pregnancy in affected patients (Figure 1). In 16 out of 18 pregnancies, patients experienced weakness. Weakness improved during 13 pregnancies (81.3%), stayed the same during 2 pregnancies (12.5%), and worsened during one (6.3%). All 10 patients experienced cutaneous rash during all 18 pregnancies carried to live birth. Cutaneous rash improved during 13 pregnancies (72.2%), remain unchanged during 3 (16.7%), and worsened during 2 (11.1%). Five patients experienced arthralgias or arthritis in a total of 11 pregnancies. Symptoms improved during 10 of these pregnancies (91%) and worsened during one (9%).There were no cases of interstitial lung disease, cancer or antiphospholipid antibody syndrome among the 10 patients studied. One patient suffered from pre-eclampsia while diagnosed with DM. 3 total pregnancy losses: two early miscarriages (< 10 weeks gestation) one therapeutic abortion for an ectopic pregnancy. 3 neonates out of 18 live births went to the NICU after delivery – reasons for transfer: meconium aspiration; apnea and pre- term birth.

Conclusion: Pregnancy does not appear to carry a worse prognosis for DM patients and all but one of our patients experienced improvement in clinical symptoms during pregnancy.


Disclosure: G. Miller, None; E. Moore, None; A. Valenzuela, None; L. Chung, None; V. P. Werth, None.

To cite this abstract in AMA style:

Miller G, Moore E, Valenzuela A, Chung L, Werth VP. Dermatomyositis and Pregnancy: Assessment of Disease Activity and Pregnancy Outcomes Complicated By Maternal Dermatomyositis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/dermatomyositis-and-pregnancy-assessment-of-disease-activity-and-pregnancy-outcomes-complicated-by-maternal-dermatomyositis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dermatomyositis-and-pregnancy-assessment-of-disease-activity-and-pregnancy-outcomes-complicated-by-maternal-dermatomyositis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology